Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?. (2nd January 2016)

• Record Type: Journal Article
• Authors: Bronte, Giuseppe; Passiglia, Francesco; Galvano, Antonio; Russo, Antonio
• Is Part Of: Expert opinion on biological therapy. Volume 16:Number 1(2016:Jan.)
• Page Start: 1
• Page End: 5
• Publication Date: 2016-01-02
• Subjects: angiogenesis -- docetaxel -- nintedanib -- NSCLC -- ramucirumab; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1517/14712598.2015.1075000
• Languages: English
• ISSNs: 1471-2598

Abstract

Abstract : Tumor angiogenesis is one of the main pathways targeted to treat cancer. Bevacizumab added survival benefit when combined with platinum-based chemotherapy in NSCLC. Recently, Phase III trials showed survival benefit when anti-angiogenic drugs are added to docetaxel as second-line treatment for NSCLC. These anti-angiogenic agents include nintedanib and ramucirumab, a tyrosine-kinase inhibitor and a monoclonal antibody, respectively, which target receptors involved in angiogenesis. These studies have some similarities and differences. We propose a new algorithm for treatment sequences in performance status 0-1 patients with non-oncogene-addicted NSCLC type adenocarcinoma. Indeed clearer scientific evidences are available for this subgroup of patients.